BerGenBio ASA
Manufacturing · Norway · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Møllendalsbakken 9, Berger, Vestfold, 30...Phone Number
+47 55961159Website
www.bergenbio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About BerGenBio ASA
Oncoinvent ASA specializes in developing innovative therapies, particularly first-in-class AXL inhibitors aimed at treating aggressive diseases. The company focuses on advancing its clinical trials, including a Phase 2 trial and a Phase 1 study for ovarian cancer. Intended clients include patients suffering from severe conditions and healthcare providers seeking advanced treatment options. Oncoinvent ASA emerged from the merger of BerGenBio ASA and Oncoinvent ASA, enhancing its capabilities in the biopharmaceutical sector.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BerGenBio ASA your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when BerGenBio ASA launches new products
Earning: See what the market has to say on BerGenBio ASA recently announced quarterly report
Funding: Get notified immidiatlly once BerGenBio ASA has new funding data
Click to see if BerGenBio ASA had a recent Job posting/layoffs
Check out if BerGenBio ASA is spiking on competitors!
BerGenBio ASA, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at BerGenBio ASA
Check if BerGenBio ASA has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at BerGenBio ASA
Find 2 more new buyers
Company Profile Activity
Activity Insights
BerGenBio ASA is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
BerGenBio ASA is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about BerGenBio ASA.
BerGenBio ASA financials insights
Gather financial insights about BerGenBio ASA, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Unspecified
$1.3M
2012
Series A
$8.8M
2014
Unspecified
$11.3M
Private Equity
$12.2M
2016
Private Equity
$25.2M
2017
Grant
$2.9M
BerGenBio ASA Tech Stack
A closer look at the technologies used by BerGenBio ASA
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Executive Move
Executive Moves, Board of Directors
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
BerGenBio ASA News & Media
Announcement of fully underwritten rights issue
OSLO, Norway, June 30, 2025 /PRNewswire/ -- BerGenBio ASA the ("Company") hereby announces a fully underwritten rights issue with preferential subscription rights (the "Subscription Rights") for the Company's existing shareholders at the time of completion of the proposed merger between...BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer therapies, announce proposed merger and a fully underwritten rights issue
OSLO, Norway, June 30, 2025 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO) ("BerGenBio" or the "Company") and Oncoinvent ASA (OSE: ONCIN) ("Oncoinvent") announce that they have entered into a merger agreement (the "Agreement") to combine the two companies through a statutory merger (the...BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer therapies, announce proposed merger and a fully underwritten rights issue
OSLO, Norway, June 30, 2025 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO) ("BerGenBio" or the "Company") and Oncoinvent ASA (OSE: ONCIN) ("Oncoinvent") announce that they have entered into a merger agreement (the "Agreement") to combine the two companies through a statutory merger (the...BerGenBio Announces First Patient Entered Into Advanced Adenocarcinoma Lung Cancer Trial
BERGEN, Norway, Jan. 7, 2025 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing the novel, selective AXL kinase inhibitor bemcentinib for lung cancer announced today that the first patient has been included in a clinical trial sponsored by...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BerGenBio ASA
Sign Up For FreeTo access detailed company insights
Oncoinvent ASA specializes in developing innovative therapies, particularly first-in-class AXL inhibitors aimed at treating aggressive diseases. The company focuses on advancing its clinical trials, including a Phase 2 trial and a Phase 1 study for ovarian cancer. Intended clients include patients suffering from severe conditions and healthcare pro... Read More
